Avelumab + Bevacizumab + Capecitabine + Cisplatin + Cyclophosphamide + 5-fluorouracil + Leucovorin + nab-Paclitaxel + omega-3-acid ethyl esters + ALT-803 + ETBX-051 + ETBX-061 + GI-6301 + haNK
Phase 1/2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma
Trial Timeline
Dec 1, 2017 → Dec 28, 2021
NCT ID
NCT03167164About Avelumab + Bevacizumab + Capecitabine + Cisplatin + Cyclophosphamide + 5-fluorouracil + Leucovorin + nab-Paclitaxel + omega-3-acid ethyl esters + ALT-803 + ETBX-051 + ETBX-061 + GI-6301 + haNK
Avelumab + Bevacizumab + Capecitabine + Cisplatin + Cyclophosphamide + 5-fluorouracil + Leucovorin + nab-Paclitaxel + omega-3-acid ethyl esters + ALT-803 + ETBX-051 + ETBX-061 + GI-6301 + haNK is a phase 1/2 stage product being developed by ImmunityBio for Merkel Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03167164. Target conditions include Merkel Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03167164 | Phase 1/2 | Withdrawn |
Competing Products
20 competing products in Merkel Cell Carcinoma